Company Name | Onyx Biotec Limited |
Open Date | 13-11-2024 |
Close Date | 18-11-2024 |
Exchange | NSE SME |
Lot Size | 2,000 Shares |
Issue Price | ₹58 to ₹61 per share |
Issue Size | 48,10,000 shares |
Application Amount | ₹1,22,000 |
Recommendation | Avoid |
For the Period Ended | Mar-22 | Mar-23 | Mar-24 |
Revenue | 4,486.14 | 3,948.19 | 5,374.88 |
EBITDA | 563.85 | 445.80 | 828.22 |
Net Profit | 335.31 | 183.47 | 303.17 |
RoCE | 15.63% | 7.70% | 11.71% |
ROE | 20.48% | 10.08% | 12.19% |
P/E | 21.48 | 39.10 | 24.02 |
Opening Date | 13-11-2024 |
Closing Date | 18-11-2024 |
Basis of Allotment | 19-11-2024 |
Initiation of Refunds | 20-11-2024 |
Credit of Shares to Demat | 20-11-2024 |
Listing Date | 21-11-2024 |
Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use |
Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections |
Prepayment or repayment of all or a portion of certain loans availed by the Company |
General Corporate Purposes |
Registered Office | Onyx Biotec Limited Bir Plassi Near Sainimajraropar, Nalagarh Road District Solan – 174101 |
Phone | +91 172 265 6384 |
generalinfo@onyxbiotec.com | |
Website | http://www.onyxbiotec.com/ |
Onyx Biotec IPO DRHP |
Onyx Biotec IPO RHP |
Name | Mas Services Limited |
Phone | (011) 2610 4142 |
ipo@masserv.com | |
Website | https://www.masserv.com/opt.asp |
QIB Shares Offered | Not more than 49.89% of the Net Issue |
Retail Shares Offered | Not less than 35.04% of the Net Issue |
NII (HNI) Shares Offered | Not less than 15.07% of the Net Issue |
Shareholding Pre Issue (Promoters) | 88.60% |
Shareholding Post Issue (Promoters) | 65.10% |